Myo‐inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aim: To investigate hormonal dynamics in a group of non‐obese polycystic ovary syndrome (PCOS) patients under myo‐inositol (MYO) administration. Methods: Hormonal profiles, insulin response to oral glucose tolerance test (OGTT) and luteinizing hormone (LH) response to gonadotropin‐releasing hormone (GnRH) stimulation test before and after the administration of a preparation of MYO (3 g p.o. daily) mixed with lactoferrin and bromelin, in a group (n = 24) of normal weight PCOS patients. Results: After the treatment interval, body mass index (BMI) did not change while LH, LH/follicle‐stimulating hormone, 17‐hydroxy‐progesterone and androstenedione decreased significantly. Insulin response to OGTT was significantly reduced after the treatment interval (P < 0.05) as well as GnRH‐induced LH response (P < 0.05). High‐sensitivity C‐reactive protein decreased significantly after the treatment interval. Conclusion: MYO administration positively modulates insulin sensitivity in non‐obese PCOS patients without compensatory hyperinsulinemia, improving hormonal parameters. The presence of bromelin in the formulation modulated the pro‐inflammatory state that characterizes PCOS, independently of BMI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“Various studies and reviews support the role of inositol as a modulator of the insulin-mediated metabolic pathway(s) in particular in patients with PCOS and insulin resistance.(2,13,16,19,29) Inositol is an IPG second messenger that transfers the biological signal induced by the linkage of insulin with its own membran…”
ResultRetractedMetformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 2×
“without hyperinsulinemia, they showed changes similar to those previously reported for overweight PCOS patients treated with MYO(19,20,22) or with DCI.(15) Though our study is limited by the fact of not having a placebo-treated arm that should have been performed to make the present study more complete, the changes”
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221
Self-citationEffects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Sun, T.-H., Heimark, D. B., Nguygen, T., Nadler, J. L., & Larner, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00313-3 · Cited by 144 · cited 1×
“MYO is then transformed by an epimerase in DCI, with each tissue having its own conversion rate, likely due to the specific needs of the two different molecules.(14,18) Recent studies and reviews clearly demonstrated that MYO administration improves insulin resistance in PCOS patients, correcting also the hormonal pro…”
BackgroundUse of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
Self-citationd-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review
Galazis, N., Galazi, M., & Atiomo, W. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2010.538099 · Cited by 46 · cited 1×
“Various studies and reviews support the role of inositol as a modulator of the insulin-mediated metabolic pathway(s) in particular in patients with PCOS and insulin resistance.(2,13,16,19,29) Inositol is an IPG second messenger that transfers the biological signal induced by the linkage of insulin with its own membran…”
Result
Cited by
Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-022-01091-0 · Cited by 408
Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach
Toosy, S., Sodi, R., & Pappachan, J. M. (2018) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0371-5 · Cited by 154
Debates regarding lean patients with polycystic ovary syndrome: a narrative review
Dawood, A., & Goyal, M. (2017) · Journal of Human Reproductive Sciences · doi:10.4103/jhrs.jhrs_77_17 · Cited by 72
Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome
Mansour, A., Hosseini, S., Larijani, B., & Mohajeri-Tehrani, M. R. (2016) · IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund · doi:10.17179/excli2016-422 · Cited by 15
Non-pharmacological management of gestational diabetes: The role of myo-inositol
Guardo, F. D., Currò, J. M., Valenti, G., Rossetti, P., Di Gregorio, L. M., Conway, F., Chiofalo, B., Garzon, S., Bruni, S., & Rizzo, G. (2020) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2019-0111 · Cited by 14
Metadata
- Authors
- Genazzani, A. D., Santagni, S., Ricchieri, F., Campedelli, A., Rattighieri, E., Chierchia, E., Marini, G., Despini, G., Prati, A., & Simoncini, T.
- Venue
- Journal of Obstetrics and Gynaecology Research
- Publisher
- Wiley
- Published
- 2014-03-09
- Volume
- 40
- Issue
- 5
- Pages
- 1353-1360
- ISSN
- 1341-8076 (ISSN-L)
- 1447-0756
- OpenAlex
- W1534193011
- Cited by
- 31
- References
- 8
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.